Smooth Muscle Mineralocorticoid Receptor Promotes Hypertension After Preeclampsia.


Journal

Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103

Informations de publication

Date de publication:
17 03 2023
Historique:
pubmed: 24 2 2023
medline: 21 3 2023
entrez: 23 2 2023
Statut: ppublish

Résumé

Preeclampsia is a syndrome of high blood pressure (BP) with end organ damage in late pregnancy that is associated with high circulating soluble VEGF receptor (sFlt1 [soluble Fms-like tyrosine kinase 1]). Women exposed to preeclampsia have a substantially increased risk of hypertension after pregnancy, but the mechanism remains unknown, leaving a missed interventional opportunity. After preeclampsia, women have enhanced sensitivity to hypertensive stress. Since smooth muscle cell mineralocorticoid receptors (SMC-MR) are activated by hypertensive stimuli, we hypothesized that high sFlt1 exposure in pregnancy induces a postpartum state of enhanced SMC-MR responsiveness. Postpartum BP response to high salt intake was studied in women with prior preeclampsia. MR transcriptional activity was assessed in vitro in sFlt1-treated SMC by reporter assays and PCR. Preeclampsia was modeled by transient sFlt1 expression in pregnant mice. Two months post-partum, mice were exposed to high salt and then to AngII (angiotensin II) and BP and vasoconstriction were measured. Women exposed to preeclampsia had significantly enhanced salt sensitivity of BP verses those with a normotensive pregnancy. sFlt1 overexpression during pregnancy in mice induced elevated BP and glomerular endotheliosis, which resolved post-partum. The sFlt1 exposed post-partum mice had significantly increased BP response to 4% salt diet and to AngII infusion. In vitro, SMC-MR transcriptional activity in response to aldosterone or AngII was significantly increased after transient exposure to sFlt1 as was aldosterone-induced expression of AngII type 1 receptor. Post-partum, SMC-MR-KO mice were protected from the enhanced response to hypertensive stimuli after preeclampsia. Mechanistically, preeclampsia mice exposed to postpartum hypertensive stimuli develop enhanced aortic stiffness, microvascular myogenic tone, AngII constriction, and AngII type 1 receptor expression, all of which were prevented in SMC-MR-KO littermates. These data support that sFlt1-induced vascular injury during preeclampsia produces a persistent state of enhanced sensitivity of SMC-MR to activation. This contributes to postpartum hypertension in response to common stresses and supports testing of MR antagonism to mitigate the increased cardiovascular risk in women after PE.

Sections du résumé

BACKGROUND
Preeclampsia is a syndrome of high blood pressure (BP) with end organ damage in late pregnancy that is associated with high circulating soluble VEGF receptor (sFlt1 [soluble Fms-like tyrosine kinase 1]). Women exposed to preeclampsia have a substantially increased risk of hypertension after pregnancy, but the mechanism remains unknown, leaving a missed interventional opportunity. After preeclampsia, women have enhanced sensitivity to hypertensive stress. Since smooth muscle cell mineralocorticoid receptors (SMC-MR) are activated by hypertensive stimuli, we hypothesized that high sFlt1 exposure in pregnancy induces a postpartum state of enhanced SMC-MR responsiveness.
METHODS
Postpartum BP response to high salt intake was studied in women with prior preeclampsia. MR transcriptional activity was assessed in vitro in sFlt1-treated SMC by reporter assays and PCR. Preeclampsia was modeled by transient sFlt1 expression in pregnant mice. Two months post-partum, mice were exposed to high salt and then to AngII (angiotensin II) and BP and vasoconstriction were measured.
RESULTS
Women exposed to preeclampsia had significantly enhanced salt sensitivity of BP verses those with a normotensive pregnancy. sFlt1 overexpression during pregnancy in mice induced elevated BP and glomerular endotheliosis, which resolved post-partum. The sFlt1 exposed post-partum mice had significantly increased BP response to 4% salt diet and to AngII infusion. In vitro, SMC-MR transcriptional activity in response to aldosterone or AngII was significantly increased after transient exposure to sFlt1 as was aldosterone-induced expression of AngII type 1 receptor. Post-partum, SMC-MR-KO mice were protected from the enhanced response to hypertensive stimuli after preeclampsia. Mechanistically, preeclampsia mice exposed to postpartum hypertensive stimuli develop enhanced aortic stiffness, microvascular myogenic tone, AngII constriction, and AngII type 1 receptor expression, all of which were prevented in SMC-MR-KO littermates.
CONCLUSIONS
These data support that sFlt1-induced vascular injury during preeclampsia produces a persistent state of enhanced sensitivity of SMC-MR to activation. This contributes to postpartum hypertension in response to common stresses and supports testing of MR antagonism to mitigate the increased cardiovascular risk in women after PE.

Identifiants

pubmed: 36815487
doi: 10.1161/CIRCRESAHA.122.321228
pmc: PMC10119809
mid: NIHMS1875730
doi:

Substances chimiques

FLT1 protein, human EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-1 EC 2.7.10.1
Receptors, Mineralocorticoid 0
Aldosterone 4964P6T9RB

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

674-689

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL119290
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL096141
Pays : United States
Organisme : NHLBI NIH HHS
ID : R56 HL118085
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007609
Pays : United States
Organisme : NHLBI NIH HHS
ID : K99 HL161321
Pays : United States
Organisme : NIGMS NIH HHS
ID : R25 GM066567
Pays : United States
Organisme : NHLBI NIH HHS
ID : F30 HL152505
Pays : United States

Références

Hypertension. 2013 Oct;62(4):802-8
pubmed: 23980074
Am J Obstet Gynecol. 2013 May;208(5):388.e1-388.e10
pubmed: 23497796
Circ Res. 2019 Mar 29;124(7):1094-1112
pubmed: 30920918
Am J Hypertens. 2004 Oct;17(10):994-1001
pubmed: 15485766
Am J Obstet Gynecol. 2007 Apr;196(4):396.e1-7; discussion 396.e7
pubmed: 17403433
Cardiovasc Res. 2023 Jan 18;118(17):3386-3400
pubmed: 35020830
Am J Physiol Heart Circ Physiol. 2010 Jan;298(1):H189-93
pubmed: 19915174
JACC CardioOncol. 2019 Sep;1(1):14-23
pubmed: 32984850
Science. 2021 Jul 30;373(6554):
pubmed: 34326210
Hypertension. 2007 Mar;49(3):612-7
pubmed: 17210828
N Engl J Med. 2004 Feb 12;350(7):672-83
pubmed: 14764923
JCI Insight. 2018 Mar 22;3(6):
pubmed: 29563335
FASEB J. 2012 Oct;26(10):4373-82
pubmed: 22798426
Circulation. 2010 Aug 3;122(5):478-87
pubmed: 20644016
Hypertension. 2017 Oct;70(4):798-803
pubmed: 28893895
Mol Cell Endocrinol. 2012 Mar 24;350(2):256-65
pubmed: 21723914
Front Endocrinol (Lausanne). 2019 Aug 23;10:584
pubmed: 31507534
Hypertension. 2022 Jul;79(7):1536-1547
pubmed: 35510543
Hypertension. 2017 Aug;70(2):382-389
pubmed: 28652473
J Clin Invest. 2016 Jul 1;126(7):2561-74
pubmed: 27270170
Clin Exp Pharmacol Physiol. 2013 Dec;40(12):929-36
pubmed: 24111570
Am J Obstet Gynecol. 2022 Feb;226(2S):S876-S885
pubmed: 32717255
J Cell Physiol. 2001 Sep;188(3):359-68
pubmed: 11473363
Hypertension. 2010 May;55(5):1239-45
pubmed: 20308605
Curr Oncol Rep. 2022 Apr;24(4):463-474
pubmed: 35179707
Endocr Res. 2004 Nov;30(4):611-6
pubmed: 15666800
Clin Sci (Lond). 2017 Nov 23;131(23):2777-2789
pubmed: 29042489
Am J Physiol Heart Circ Physiol. 2020 Mar 1;318(3):H581-H589
pubmed: 32004082
Hypertension. 2006 Jun;47(6):1168-74
pubmed: 16618835
Hypertension. 2021 Jun;77(6):2117-2126
pubmed: 33934622
Ultrasound Obstet Gynecol. 2020 Jul;56(1):44-50
pubmed: 31613410
Hypertension. 2015 Apr;65(4):863-70
pubmed: 25712723
Cardiovasc Res. 2002 Jul;55(1):201-12
pubmed: 12062723
Nat Rev Cardiol. 2018 Sep;15(9):499-500
pubmed: 30065260
Circulation. 2010 Aug 10;122(6):579-84
pubmed: 20660802
JAMA Netw Open. 2020 Dec 1;3(12):e2030815
pubmed: 33351087
BMJ Open. 2013 Dec 23;3(12):e003733
pubmed: 24366578
Nat Med. 2012 Sep;18(9):1429-33
pubmed: 22922412
Ultrasound Obstet Gynecol. 2017 Jul;50(1):93-99
pubmed: 27256927
Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):799-805
pubmed: 17234727
N Engl J Med. 2016 Jan 7;374(1):13-22
pubmed: 26735990
J Physiol. 2016 Dec 1;594(23):7027-7047
pubmed: 27531064
Hypertension. 2018 Jun;71(6):1083-1090
pubmed: 29686001
Circulation. 2012 Feb 21;125(7):911-9
pubmed: 22261192
Hypertension. 2010 Jun;55(6):1476-83
pubmed: 20421514
Hypertension. 2018 Apr;71(4):609-621
pubmed: 29463624
Curr Opin Pharmacol. 2011 Apr;11(2):175-9
pubmed: 21317038
Am J Physiol Renal Physiol. 2014 Oct 15;307(8):F901-7
pubmed: 25164079
Circ Res. 2016 May 13;118(10):1626-42
pubmed: 27174954
Arterioscler Thromb Vasc Biol. 2011 Aug;31(8):1871-80
pubmed: 21617142
Lancet. 2021 Jul 24;398(10297):341-354
pubmed: 34051884
Am J Hypertens. 2019 Jan 15;32(2):123-134
pubmed: 30380007
JCI Insight. 2016 Sep 08;1(14):e88942
pubmed: 27683672
Nat Rev Nephrol. 2013 Feb;9(2):86-98
pubmed: 23296296
Curr Hypertens Rep. 2013 Apr;15(2):114-21
pubmed: 23397213
J Physiol. 2017 Jul 15;595(14):4735-4753
pubmed: 28475214
Hypertension. 2010 Jul;56(1):166-71
pubmed: 20516394
Endocrinology. 2019 Sep 1;160(9):2101-2114
pubmed: 31373631
J Clin Invest. 2003 Mar;111(5):649-58
pubmed: 12618519
Circ Res. 2005 Apr 1;96(6):643-50
pubmed: 15718497
J Clin Endocrinol Metab. 2011 Nov;96(11):3517-24
pubmed: 21880804
JCI Insight. 2018 Apr 19;3(8):
pubmed: 29669946
PLoS One. 2016 Sep 22;11(9):e0162487
pubmed: 27658290
Am J Obstet Gynecol. 2022 Feb;226(2S):S1019-S1034
pubmed: 33096092
Am J Physiol Heart Circ Physiol. 2021 Jan 1;320(1):H169-H180
pubmed: 33095647
Am J Physiol Regul Integr Comp Physiol. 2017 May 1;312(5):R664-R670
pubmed: 28202440
Front Med (Lausanne). 2018 Nov 30;5:325
pubmed: 30560128
Lancet. 2005 Nov 19;366(9499):1797-803
pubmed: 16298217
Women Birth. 2020 Nov;33(6):583-591
pubmed: 32035798
BMJ. 2007 Nov 10;335(7627):974
pubmed: 17975258

Auteurs

Lauren A Biwer (LA)

Molecular Cardiology Research Institute, Tufts Medical Center, Boston MA (L.A.B., Q.L., J.I., A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).

Qing Lu (Q)

Molecular Cardiology Research Institute, Tufts Medical Center, Boston MA (L.A.B., Q.L., J.I., A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).

Jaime Ibarrola (J)

Molecular Cardiology Research Institute, Tufts Medical Center, Boston MA (L.A.B., Q.L., J.I., A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).

Alec Stepanian (A)

Molecular Cardiology Research Institute, Tufts Medical Center, Boston MA (L.A.B., Q.L., J.I., A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).
Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA (A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).

Joshua J Man (JJ)

Molecular Cardiology Research Institute, Tufts Medical Center, Boston MA (L.A.B., Q.L., J.I., A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).
Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA (A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).

Brigett V Carvajal (BV)

Molecular Cardiology Research Institute, Tufts Medical Center, Boston MA (L.A.B., Q.L., J.I., A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).
Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA (A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).

Nicholas D Camarda (ND)

Molecular Cardiology Research Institute, Tufts Medical Center, Boston MA (L.A.B., Q.L., J.I., A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).
Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA (A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).

Zsuzsanna Zsengeller (Z)

Department of Medicine, Beth Israel Deaconess Hospital, Boston MA (Z.Z.).

Geraldine Skurnik (G)

Division of Endocrinology, Brigham and Women's Hospital, Boston, MA (G.S., E.W.S.).

Ellen W Seely (EW)

Division of Endocrinology, Brigham and Women's Hospital, Boston, MA (G.S., E.W.S.).

S Ananth Karumanchi (SA)

Department of Medicine, Cedars Sinai Medical Center, Los Angeles (S.A.K.).

Iris Z Jaffe (IZ)

Molecular Cardiology Research Institute, Tufts Medical Center, Boston MA (L.A.B., Q.L., J.I., A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).
Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, MA (A.S., J.J.M., B.V.C., N.D.C., I.Z.J.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH